Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease

In obese patients, non-alcoholic fatty liver (NAFLD) is common. However, whether there is a connection between the gut microbiota and the onset of NAFLD in obese people is yet unknown. Using quantitative real-time PCR, the microbiota of feces of the eligible 181 obese individuals was identified to compare the differences in gut microbiota between obesity with NAFLD and simple obesity. According to the findings, the gut dominant microbiota was similar between obesity with NAFLD and simple obesity. Nonetheless, compared to the simple obesity group, the quantity of Faecalibacterium prausnitzii colonies was much lower in the obesity with the NAFLD group. Bacteroides were present in greater than 65% of both groups. Bacteroides, Clostridium leptum, and Clostridium butyricum accounted for more than 80% of the cases in the obesity with NAFLD group, whereas Bacteroides, Clostridium butyricum, and F. prausnitzii accounted for more than 80% of the cases in the simple obesity group. We look for potential contributing variables to obesity-related NAFLD and potential prevention measures for obese people. Based on a multi-factor logistic regression analysis, lymphocytes may be a risk factor for obesity with NAFLD while F. prausnitzii may be a protective factor. Additionally, F. prausnitzii is positively impacted by Bacteroides, Clostridium leptum, Clostridium butyricum, and Eubacterium rectale, yet adversely impacted by Enterobacteriaceae. Notably, lymphocytes and F. prausnitzii may help determine whether obese patients would develop NAFLD.

[1]  J. Roblero,et al.  The immune response as a therapeutic target in non-alcoholic fatty liver disease , 2022, Frontiers in Immunology.

[2]  P. Wiklund,et al.  A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease , 2022, Nature Communications.

[3]  Dongya Zhang,et al.  Microbiota in health and diseases , 2022, Signal Transduction and Targeted Therapy.

[4]  V. Ayala,et al.  NAFLD and the Gut-Liver Axis: Exploring an Undernutrition Perspective. , 2022, Gastroenterology.

[5]  E. Comelli,et al.  Relationship Between Hepatic Gene Expression, Intestinal Microbiota, and Inferred Functional Metagenomic Analysis in NAFLD , 2022, Clinical and translational gastroenterology.

[6]  F. Bäckhed,et al.  The Metabolic Role and Therapeutic Potential of the Microbiome , 2022, Endocrine reviews.

[7]  F. Magkos,et al.  Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives , 2021, Biomolecules.

[8]  V. Tremaroli,et al.  Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. , 2021, European heart journal.

[9]  A. Rosengren Obesity and cardiovascular health: the size of the problem , 2021, European heart journal.

[10]  M. Honda,et al.  Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics , 2021, International journal of molecular sciences.

[11]  Changtao Jiang,et al.  Intestinal hypoxia-inducible factor 2α regulates lactate levels to shape the gut microbiome and alter thermogenesis. , 2021, Cell metabolism.

[12]  Xusheng Guo,et al.  Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates , 2021, International journal of biological sciences.

[13]  P. Fariselli,et al.  Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? , 2021, Gut.

[14]  R. Ley,et al.  The role of the microbiota in human genetic adaptation , 2020, Science.

[15]  O. Pedersen,et al.  Gut microbiota in human metabolic health and disease , 2020, Nature Reviews Microbiology.

[16]  L. Kazak,et al.  Creatine metabolism: energy homeostasis, immunity and cancer biology , 2020, Nature Reviews Endocrinology.

[17]  Luis Pedro Coelho,et al.  Statin therapy is associated with lower prevalence of gut microbiota dysbiosis , 2020, Nature.

[18]  K. Clément,et al.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders , 2020, Nature Reviews Gastroenterology & Hepatology.

[19]  K. Clément,et al.  Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? , 2020, Gastroenterology.

[20]  R. Rodrigues,et al.  Role of gut microbiota in type 2 diabetes pathophysiology , 2020, EBioMedicine.

[21]  D. Halegoua-DeMarzio,et al.  Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter? , 2019, Nutrients.

[22]  E. Albano,et al.  Adaptive immunity: an emerging player in the progression of NAFLD , 2019, Nature Reviews Gastroenterology & Hepatology.

[23]  J. Venter,et al.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. , 2019, Cell metabolism.

[24]  L. Hooper,et al.  Immune control of the microbiota prevents obesity , 2019, Science.

[25]  G. Reid,et al.  Probiotics and prebiotics in intestinal health and disease: from biology to the clinic , 2019, Nature Reviews Gastroenterology & Hepatology.

[26]  J. Raes,et al.  Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study , 2019, Nature Medicine.

[27]  Jonathan P. Jacobs,et al.  Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver? , 2019, Experimental biology and medicine.

[28]  K. Venema,et al.  Gut microbial metabolites in obesity, NAFLD and T2DM , 2019, Nature Reviews Endocrinology.

[29]  A. Ananthakrishnan,et al.  Manipulating the Microbiome With Fecal Transplantation to Treat Ulcerative Colitis. , 2019, JAMA.

[30]  William H. Bisson,et al.  Gut microbiota and intestinal FXR mediate the clinical benefits of metformin , 2018, Nature Medicine.

[31]  M. Netea,et al.  The Inhibitory Innate Immune Sensor NLRP12 Maintains a Threshold against Obesity by Regulating Gut Microbiota Homeostasis. , 2018, Cell host & microbe.

[32]  B. Schnabl,et al.  Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease , 2018, Gut.

[33]  P. Schneider,et al.  B2‐Lymphocyte responses to oxidative stress‐derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD) , 2018, Free radical biology & medicine.

[34]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[35]  P. Gentileschi,et al.  Molecular Phenomics and Metagenomics of Hepatic Steatosis in Non-Diabetic Obese Women , 2018, Nature Medicine.

[36]  Rob Knight,et al.  Current understanding of the human microbiome , 2018, Nature Medicine.

[37]  M. Nieuwdorp,et al.  Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans , 2018, Endocrine reviews.

[38]  A. Kurilshikov,et al.  Environment dominates over host genetics in shaping human gut microbiota , 2018, Nature.

[39]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[40]  Ruixin Zhu,et al.  Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD , 2017, Gut.

[41]  H. Chuang,et al.  Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis , 2017, Nutrients.

[42]  A. Kariminik,et al.  Gut Microbiota and IL-17A: Physiological and Pathological Responses , 2017, Probiotics and Antimicrobial Proteins.

[43]  Louis J. Cohen,et al.  Commensal bacteria produce GPCR ligands that mimic human signaling molecules , 2017, Nature.

[44]  Alberto Martin,et al.  Microbiome and colorectal cancer: Unraveling host-microbiota interactions in colitis-associated colorectal cancer development. , 2017, Seminars in immunology.

[45]  Huijue Jia,et al.  Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention , 2017, Nature Medicine.

[46]  K. Brandl,et al.  Intestinal microbiota and nonalcoholic steatohepatitis , 2017, Current opinion in gastroenterology.

[47]  Eveliina Munukka,et al.  Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice , 2017, The ISME Journal.

[48]  P. Paci,et al.  Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta‐omics‐based approach , 2017, Hepatology.

[49]  Tim Geach Gut microbiota: Mucin-munching bacteria modulate glucose metabolism , 2017, Nature Reviews Endocrinology.

[50]  S. Duncan,et al.  Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics , 2017, The ISME Journal.

[51]  R. Sartor,et al.  Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. , 2017, Gastroenterology.

[52]  A. Waisman,et al.  Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma. , 2016, Cancer cell.

[53]  Rohit Kohli,et al.  IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice , 2014, Hepatology.

[54]  Jie-shou Li,et al.  Microbial fingerprinting detects intestinal microbiota dysbiosis in Zebrafish models with chemically-induced enterocolitis , 2013, BMC Microbiology.

[55]  Xiaokang Wu,et al.  Molecular Characterization of Fecal Microbiota in Patients with Viral Diarrhea , 2011, Current Microbiology.

[56]  A. Palva,et al.  Development of an extensive set of 16S rDNA‐targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real‐time PCR , 2004, Journal of applied microbiology.

[57]  J. Fujimoto,et al.  Use of 16S rRNA Gene-Targeted Group-Specific Primers for Real-Time PCR Analysis of Predominant Bacteria in Human Feces , 2004, Applied and Environmental Microbiology.

[58]  S. Finegold,et al.  Real-Time PCR Quantitation of Clostridia in Feces of Autistic Children , 2004, Applied and Environmental Microbiology.

[59]  M. Mcmurdo,et al.  Characterization of Bacterial Communities in Feces from Healthy Elderly Volunteers and Hospitalized Elderly Patients by Using Real-Time PCR and Effects of Antibiotic Treatment on the Fecal Microbiota , 2004, Applied and Environmental Microbiology.

[60]  C. Nishida,et al.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies , 2004, The Lancet.